<DOC>
	<DOC>NCT01103518</DOC>
	<brief_summary>This is a Phase IV, randomized, double-blind, comparative study of the use of two preparations of ethinyl estradiol and cyproterone acetate in the treatment of menstrual irregularities of hyper-androgenic origin.</brief_summary>
	<brief_title>Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Menstruation Disturbances</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Female subject Premenopausal subject 18 years or older Medical history of irregular menses lasting at least 3 months Signature of informed consent Pregnancy Use of hormonal contraceptives within 3 months of screening Primary bilateral oophorectomy Chemotherapy and / or radiotherapy within 6 months of screening Hysterectomy Myotonic dystrophy Galactosemia Galactorrhea History of tuberculosis or schistosomiasis Elevated prolactin / other significant laboratory alterations Diabetes Premature ovarian deficiency Sensitivity to any component of the drug formula</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Menstrual irregularity</keyword>
	<keyword>Menstruation disturbances</keyword>
	<keyword>Hyperandrogenism</keyword>
</DOC>